Table 2.

Survival: NCICCCs vs. Non-NCICCC Facilities

Primary Diagnosis	5-year Overall Survival (OS)a		Likelihood of Mortalitya
	OS (95% CI)	p-value	HR (95% CI)	p-value
Full Cohort
NCICCC	64.3% (62.8–65.8%)	<0.001	1.0	<0.001
Non-NCICCC	60.7% (60.3–61.1%)		1.3 (1.2–1.3)
Hepatobiliary
NCICCC	33.8% (29.6–38.1%)	<0.001	1.0	<0.001
Non-NCICCC	18.7% (17.3–20.1%)		1.5 (1.4–1.7)
Lung
NCICCC	27.7% (23.3–32.1%)	<0.001	1.0	<0.001
Non-NCICCC	17% (15.7–17.3%)		1.4 (1.3–1.6)
Pancreas
NCICCC	12.5% (7.8–17.2%)	<0.001	1.0	<0.001
Non-NCICCC	6.2% (5.0–7.4%)		1.5 (1.3–1.7)
Gastric
NCICCC	30.7% (22.0–39.4%)	0.007	1.0	0.01
Non-NCICCC	22.2% (20.4–24.0%)		1.3 (1.1–1.7)
Breast b,c
NCICCC	88.6% (87.1–90.2%)	<0.001	1.0	<0.001
Non-NCICCC	85.9% (85.5–86.4%)		1.3 (1.1–1.5)
Cervix c
NCICCC	76.9% (69.4–84.4%)	0.27	1.0	0.07
Non-NCICCC	73.3% (71.7–74.9%		1.3 (0.9–1.9)
Oral
NCICCC	68.5% (62.3–74.7%)	0.009	1.0	0.09
Community	58.8% (56.2–61.4%)		1.2 (1.0–1.5)
Colorectal
NCICCC	62.8% (58.1–67.5%)	0.31	1.0	0.05
Non-NCICCC	62.6% (61.6–63.6%)		1.2 (1.0–1.4)

^aMultivariable Cox regression, adjusted for age, gender, stage, race/ethnicity, SES, payor

^bAdjusted for histology.

^cFemales.